Stocks rise 65.9% post-IPO for newly public biotech companies
This article was originally published in Scrip
Executive Summary
Biotechnology investment bubble or not, the average return on investment for 29 drug developers that launched initial public offerings during the first nine months of the year is 65.9%. That's a compelling figure for companies trying to decide if they should go public in 2013 and for investors considering whether to participate in biotech IPOs.